MARC-2: MARKERS AND RESPONSE TO CRT in Non-LBBB (MARC-2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04120909|
Recruitment Status : Recruiting
First Posted : October 9, 2019
Last Update Posted : October 9, 2019
The purpose of the MARC-2 study is to investigate the relation of the QRS area, determined by vectorcardiography, and response to Cardiac Resynchronization Therapy (CRT) in patients with a wide QRS complex and without a typical left bundle branch block; the interrelationship as well as the potential predictive power of this biomarker, as well as other clinical biomarkers on a hierarchal composite endpoint (death, heart failure hospitalizations, heart failure complaints and cardiac function) will be evaluated.
The main biomarker that is studied is the QRS area, but also other electrocardiographic, echocardiographic markers, blood markers and clinical markers will be studied.
|Condition or disease||Intervention/treatment|
|Cardiac Resynchronization Therapy, Non-LBBB, QRS Area||Device: Cardiac resynchronization therapy|
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||MARC-2: MARKERS AND RESPONSE TO CRT in Non-LBBB|
|Actual Study Start Date :||August 26, 2019|
|Estimated Primary Completion Date :||August 2022|
|Estimated Study Completion Date :||August 2022|
- Device: Cardiac resynchronization therapy
Biventricular pacing according to current standards.
- CRT response score will assess patient improvement including all-cause mortality, heart failure hospitalization, LVESVi reduction, and NYHA class improvement [ Time Frame: 12 months ]Hierarchical endpoint based upon the concepts presented by Packer (Packer, Circulation 2016)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04120909
|Contact: Kevin Vernooy, dr.||+31(0)firstname.lastname@example.org|
|Contact: Mohammed Ghossein, drs.||+31(0)email@example.com|
|Contact: Mohammed Ghossein, drs. +31(0)433884520 firstname.lastname@example.org|